TScan Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: TScan Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
TScan Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 68.9 %, a 9.76% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	68.9	-7.46	-9.76%	Jun 30, 2024
Q1 2024	77	+14.8	+23.9%	Mar 31, 2024
Q4 2023	79.1	+40.3	+104%	Dec 31, 2023
Q3 2023	82.7	+61.2	+284%	Sep 30, 2023
Q2 2023	76.4	+59.8	+361%	Jun 30, 2023
Q1 2023	62.2	+35.7	+135%	Mar 31, 2023
Q4 2022	38.9			Dec 31, 2022
Q3 2022	21.5			Sep 30, 2022
Q2 2022	16.6			Jun 30, 2022
Q1 2022	26.5			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.